Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy

Documenti analoghi

• VTD combination therapy with bortezomib–thalidomide–dexamethasone is highly effective in advanced and refractory multiple myeloma
  di: Pineda-Roman, M, et al.
  Pubblicazione: (2008)
• International Staging System and Metaphase Cytogenetic Abnormalities in the Era of Gene Expression Profiling Data in Multiple Myeloma Treated with Total Therapy 2 and 3 Protocols
  di: Waheed, Sarah, et al.
  Pubblicazione: (2010)
• Superior results of Total Therapy 3 (2003-33) in gene expression profiling–defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance
  di: Nair, Bijay, et al.
  Pubblicazione: (2010)
• Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols
  di: Hoering, Antje, et al.
  Pubblicazione: (2009)
• Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1
  di: Heuck, Christoph J, et al.
  Pubblicazione: (2012)